A Protocol to Evaluate Semi-Rigid Pedicle Screw Systems

1997 ◽  
Vol 119 (3) ◽  
pp. 364-366 ◽  
Author(s):  
J. D. Clausen ◽  
V. K. Goel ◽  
K. Sairyo ◽  
M. Pfeiffer
Keyword(s):  
Pedicle Screw ◽  
In Vitro Testing ◽  
Cable System ◽  
Spinal Implants ◽  
Testing Protocol

The objective of the current study was to develop an in vitro testing protocol to evaluate semi-rigid pedicle screw devices. A corpectomy model protocol exists to evaluate rigid spinal implants; however, semi-rigid devices are contraindicated for this condition. This paper describes a technique that simulates more closely the conditions a semi-rigid device would see in vivo. Finally, the new testing protocol is used to evaluate the DDS® pedicle screw-cable system. Benefits and shortcomings of the new protocol are discussed.

In vivo and in vitro testing of gloves for protection against UV-curable acrylate resin systems

1984 ◽  
Vol 11 (5) ◽  
pp. 279-282 ◽  
Author(s):  
Robert L. Rietschel ◽  
Ronald Muggins ◽  
Nicole Levy ◽  
Pat M. Pruitt
Keyword(s):  
In Vitro Testing ◽  
Uv Curable ◽  
Acrylate Resin

Laboratory and in-vitro testing of skin antiseptics: a prediction for in-vivo activity?

1991 ◽  
Vol 18 ◽  
pp. 5-11 ◽  
Author(s):  
F. Baquero ◽  
C. Patrón ◽  
R. Cantón ◽  
M.Martínez Ferrer
Keyword(s):  
In Vitro Testing

Mining a Nanoparticle Dataset, Compiled Within the MODENA-COST Action

2021 ◽  
pp. 1706-1724
Author(s):  
Sabine Van Miert ◽  
Jan Creylman ◽  
Geert R. Verheyen
Keyword(s):  
Chemical Properties ◽  
In Vitro Testing ◽  
Cost Action ◽  
Robust Model ◽  
Physico Chemical ◽  
Classification And Regression ◽  
Toxic Potential ◽  
Sheer Number

Engineered nanomaterials (ENM) have new or enhanced physico-chemical properties compared to their micron-sized counterparts, but may also have an increased toxic potential. Animal and in vitro testing are typically employed to investigate the toxic effects of (nano)materials. The sheer number of ENMs and their physico-chemical parameters make it impossible to only use in vivo and in vitro testing, and modelling technologies are also deployed to find relationships between ENM parameters and toxicity. A heterogenous dataset containing information on 192 nanoparticle endpoints was compiled within the MODENA COST-Action consortium. Here, the available data was mined to identify relationships between nanoparticle properties and cell-death as measured with four cytotoxicity assays. ANOVA, collinearity analyses and classification and regression trees gave indications on potential relations between the NP-properties and toxicity, but could not deliver a robust model. More information and datapoints are necessary to build well-validated models.

Clindamycin anaphylaxis confirmed by in vivo and in vitro testing

2019 ◽  
Vol 7 (1) ◽  
pp. 331-333 ◽  
Author(s):  
Didier G. Ebo ◽  
Christel Mertens ◽  
Marissa Braes ◽  
Isabel Mennes ◽  
Chris H. Bridts ◽  
...  
Keyword(s):  
In Vitro Testing

Evaluation of Phase Stability in Zirconia Femoral Heads From Different Manufacturers After In Vitro Testing or In Vivo Retrieval

2009 ◽  
Vol 24 (8) ◽  
pp. 1225-1230 ◽  
Author(s):  
Kyoju Fukatsu ◽  
Giuseppe Pezzotti ◽  
Yasuhisa Hayaishi ◽  
Nobuhiko Sugano
Keyword(s):  
Phase Stability ◽  
In Vitro Testing ◽  
Femoral Heads

In vivo and in vitro testing of microelectronically fabricated planar sensors designed for applications in cardiology

1993 ◽  
Vol 346 (6-9) ◽  
pp. 584-588 ◽  
Author(s):  
Ern� Lindner ◽  
Vasile V. Cosofret ◽  
Stefan Ufer ◽  
Timothy A. Johnson ◽  
R. Bruce Ash ◽  
...  
Keyword(s):  
In Vitro Testing

Controlled-release components of PZP contraceptive vaccine extend duration of infertility

2008 ◽  
Vol 35 (6) ◽  
pp. 555 ◽  
Author(s):  
John W. Turner ◽  
Allen T. Rutberg ◽  
Ricky E. Naugle ◽  
Manpreet A. Kaur ◽  
Douglas R. Flanagan ◽  
...  
Keyword(s):  
Controlled Release ◽  
Cost Effective ◽  
Field Studies ◽  
In Vitro Testing ◽  
Fertility Reduction ◽  
Contraceptive Vaccine ◽  
Fertility Data ◽  
Controlled Release Formulations

Successful immunocontraception of wildlife relying on repeated access to individuals for boosters has highlighted the need to incorporate primer and booster immunisations into one injection. We have investigated use of controlled-release polymers (lactide–glycolide) in small pellets to provide delayed in vivo delivery of booster porcine zona pellucida (PZP) antigen and adjuvant. This report reviews pellet-making methodology, in vitro testing of controlled-release pellets and in vivo effects of controlled-release PZP vaccine. We assessed 3 different manufacturing approaches for producing reliable, cost-effective pellets: (1) polymer melting and extrusion; (2) solvent evaporation from polymer solution; and (3) punch and die polymer moulding. In vitro testing of release patterns of controlled-release formulations, towards development of a 3-year duration vaccine, provided estimates for in vivo use of pellet preparations. These in vitro studies demonstrated protein release delay up to 22 months using 100% l-lactide or polycaprolactone polymers. For in vivo tests, pellets (1-, 3-, and 12-month release delay) serving as boosters were administered intramuscularly with PZP/adjuvant liquid primer to wild horses (Equus caballus), white-tailed deer (Odocoileus virginanus) and African elephants (Loxodonta africana). Horse field studies assessed fertility via offspring counts and/or faecal-hormone pregnancy testing. Treatment decreased fertility 5.3–9.3-fold in Year 1 and 3.6-fold in Year 2. In preliminary testing in deer, offspring counts revealed treatment-associated fertility reduction of 7.1-fold Year 1 and 3.3-fold Year 2. In elephants, treatment elevated anti-PZP titres 4.5–6.9-fold from pretreatment (no fertility data).

scholarly journals Remdesivir and Lopinavir/Ritonavir as Potential Drugs to Treat Corona Virus Disease 2019

2021 ◽  
Author(s):  
Reda Bzikha ◽  
Bouhmou Ayoub ◽  
Bzikha ilham ◽  
Sanaa Bouchnafati
Keyword(s):  
Virus Disease ◽  
Antiviral Drug ◽  
In Vitro Testing ◽  
Human Coronavirus ◽  
Corona Virus

Drugs that are efficacious against SARS-CoV-2 have yet to be established. Remdesivir and Lopinavir/ritonavir have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Remdesivir not only in vivo but also in vitro testing shows the inhibition of human coronavirus replication, including SARS-CoV aswell as Lopinavir/ritonavir that shows promising antiviral drug against SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document